Literature DB >> 2590827

Effect of levamisole on parenteral vaccines for swine dysentery.

E M Jenkins, C Hurdle.   

Abstract

Leucocyte migration-inhibition and humoral antibody responses (HAR) were demonstrated in swine immunized with particulate or soluble antigen of Treponema hyodysenteriae. Levamisole (at the recommended deworming level), given simultaneously with particulate vaccine did not significantly (P greater than 0.05) enhance nor suppress the leucocyte migration-inhibition response. However, an enhancing leucocyte migration-inhibition of the drug was seen in pigs given soluble vaccine in combination with levamisole compared with those receiving soluble antigen alone. Levamisole generally suppressed the HAR throughout the immunization schedule of pigs given soluble or particulate vaccine. There was no significant suppression (P greater than 0.05) of clinical signs of swine dysentery (SD) in animals given particulate vaccine nor in those receiving this vaccine plus levamisole. However, pigs receiving soluble vaccine plus levamisole had fewer clinical signs of SD as well as significantly (P less than 0.05) fewer shedding episodes of T. hyodysenteriae than those given soluble antigen alone. When compared with the control pigs, swine vaccinated with soluble antigen had fewer days of total diarrhoea and shedding episodes of T. hyodysenteriae. However, the diarrhoea of vaccinated pigs was not significantly (P greater than 0.05) delayed when compared to the unvaccinated swine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590827     DOI: 10.1016/0007-1935(89)90119-X

Source DB:  PubMed          Journal:  Br Vet J        ISSN: 0007-1935


  1 in total

1.  Histomorphometric characteristics of immune cells in small intestine of pigs perorally immunized with vaccine candidate F18ac nonenterotoxigenic E. coli strain.

Authors:  A Kovšca Janjatović; G Lacković; F Božić; D Spoljarić; M Popović; H Valpotić; N Vijtiuk; Z Pavičić; I Valpotić
Journal:  Eur J Histochem       Date:  2009-12-29       Impact factor: 3.188

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.